drugset / Trial / NCT05082285

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

NCT05082285

Phase 2 Completed 726 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenACWY-7b) vaccine intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups, in healthy infants 2 months of age (MoA) at enrolment.

Timeline

Start
2021-11-29
Primary completion
2025-03-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MenABCWY-1Gen Vaccine Intramuscular
Subject MenACWY-7B Vaccine Intramuscular
Subject MenB Vaccine Intramuscular
Subject Menveo Vaccine Intramuscular